Home > Inhibitors & Agonists > Epigenetics > Bromodomain
Cat. No. Product name CAS No.
DC10656 (+)-JQ1 carboxylic acid Featured

(+)-JQ1 carboxylic acid is the carboxylic acid form of (+)-JQ1 for derivative synthesis.

DC5019 (+)-JQ1 Featured

(+)-JQ1 is a BET bromodomain inhibitor, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

DC12021 (+)-JQ1 PA Featured

(+)-JQ1 PA is a Click-activated (alkyne) version of the BET bromodomain inhibitor (+)-JQ1.

DC11652 Ischemin sodium

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

DC11653 Ischemin

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

DC7565 BET bromodomain inhibitor,cas 1505453-59-7

A new compound which is similar with +JQ-1,BET bromodomain inhibitor

DC11793 UMB-32

A novel a potent, selective inhibitor of BRD4 with Kd of 550 nM, cellular IC50 of 724 nM.

DC11792 UMB-136

A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation.

DC11730 GNE-207

A novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM.

DC11568 HJB-97

A potent BET bromodomian inhibitor with IC50 of 3-7 nM for BRD2/3/4 BD1 and BD2..

DC11452 ABBV-744 Featured

ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.

DC11887 Alobresib (GS-5829) Featured

Alobresib is a novel BET bromodomain inhibitor with antineoplastic activity..

DC10334 ARV-771 Featured

ARV-771 is a potent bromodomain and extra-terminal (BET) proteins degrader with Kd values of 4.7, 7.6, 7.6 nM against bromodomain 2, 3 and 4, respectively.

DC12024 ARV-825 Featured

ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.

DC10288 AZD5153 6-Hydroxy-2-naphthoic acid Featured

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.

DC10774 AZD5153 Featured

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.

DC12029 BAY-299 Featured

BAY-299 is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1 (IC50 = 6 nM).

DC11505 BAY-850 Featured

BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay.


BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

DC11042 BET inhibitor CF53

BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1).

DC8556 BET-BAY 002

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

DC9888 BI-9564 Featured

BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with Kd of 5.9 nM for BRD9, and IC50 of > 100 μM for BET family.

Page 1 / Total 6 FirstPrevNextLastGoto